FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016403707> ?p ?o ?g. }

• W2016403707 endingPage "S338" @default.
• W2016403707 startingPage "S337" @default.
• W2016403707 abstract "Background: Indoleamine 2,3-dioxygenase (IDO) is an important enzyme in the regulation of immune responses. The cells that express IDO can suppress T cell responses and promote tolerance. We have investigated the role of IDO expression by vascular endothelial cells and its overexpression by gene transfer and its consequence on immunoregulation. Many studies have now indicated that in atherosclerosis, there is a defect in the immunoregulation1. Thus far, very few investigations have been conducted to modify this defective component of immune system. We have therefore explored the role of IDO following gene transfer on immune system with a long-term goal to modulate alloresponse or atherosclerotic process. Methods ? Results: We compared the expression of IDO by primary human umbilical vein endothelial cells (HUVECs) (fetal tissues) and human saphenous vein endothelial cells (HSVECs) (adult tissues) using reverse transcriptase PCR, Western blotting and assays for enzymatic activity. IDO is constitutively expressed by HUVECs, and can be upregulated by incubation with cytokines. On the other hand, HSVEC express little IDO, which is poorly upregulated upon activation (except by mycoplasma). Inhibition of IDO activity improved the ability of HUVEC to stimulate allogeneic T cell responses. If either HUVEC or HSVEC are transfected with the gene encoding IDO then they are incapable of stimulating allogeneic T cell responses, and induce anergy in allospecific T cells, which can also act as regulatory cells. Using our immunolipoplexes targeting specifically against vascular EC 2,3, IDO construct was successfully transfected into HUVEC and HSVEC. This resulted in a functional effect on T cell tolerance induction. These data indicate that IDO is a good therapeutic gene to modulate rejection process or to modulate that the immune components seen in the chronic atherosclerosis. Conclusion: The variable expression of IDO in different endothelial cells is important not only in understanding the role of endothelial cells in the regulation of immune responses, but also as a potential therapeutic strategy through a gene-based treatment to modulate the alloresponse or the immune component of the atherosclerosis.Reference:1. Mallat, Z. et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation108, 1232–7 (2003).2. Tan, P. H. et al. Antibody targeted gene transfer to endothelium. J Gene Med5, 311–323 (2003).3. Tan, P. H. et al. Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther11, 790–800 (2005). Background: Indoleamine 2,3-dioxygenase (IDO) is an important enzyme in the regulation of immune responses. The cells that express IDO can suppress T cell responses and promote tolerance. We have investigated the role of IDO expression by vascular endothelial cells and its overexpression by gene transfer and its consequence on immunoregulation. Many studies have now indicated that in atherosclerosis, there is a defect in the immunoregulation1. Thus far, very few investigations have been conducted to modify this defective component of immune system. We have therefore explored the role of IDO following gene transfer on immune system with a long-term goal to modulate alloresponse or atherosclerotic process. Methods ? Results: We compared the expression of IDO by primary human umbilical vein endothelial cells (HUVECs) (fetal tissues) and human saphenous vein endothelial cells (HSVECs) (adult tissues) using reverse transcriptase PCR, Western blotting and assays for enzymatic activity. IDO is constitutively expressed by HUVECs, and can be upregulated by incubation with cytokines. On the other hand, HSVEC express little IDO, which is poorly upregulated upon activation (except by mycoplasma). Inhibition of IDO activity improved the ability of HUVEC to stimulate allogeneic T cell responses. If either HUVEC or HSVEC are transfected with the gene encoding IDO then they are incapable of stimulating allogeneic T cell responses, and induce anergy in allospecific T cells, which can also act as regulatory cells. Using our immunolipoplexes targeting specifically against vascular EC 2,3, IDO construct was successfully transfected into HUVEC and HSVEC. This resulted in a functional effect on T cell tolerance induction. These data indicate that IDO is a good therapeutic gene to modulate rejection process or to modulate that the immune components seen in the chronic atherosclerosis. Conclusion: The variable expression of IDO in different endothelial cells is important not only in understanding the role of endothelial cells in the regulation of immune responses, but also as a potential therapeutic strategy through a gene-based treatment to modulate the alloresponse or the immune component of the atherosclerosis. Reference: 1. Mallat, Z. et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation108, 1232–7 (2003). 2. Tan, P. H. et al. Antibody targeted gene transfer to endothelium. J Gene Med5, 311–323 (2003). 3. Tan, P. H. et al. Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther11, 790–800 (2005)." @default.
• W2016403707 created "2016-06-24" @default.
• W2016403707 creator A5050282712 @default.
• W2016403707 creator A5056234160 @default.
• W2016403707 date "2006-01-01" @default.
• W2016403707 modified "2023-09-23" @default.
• W2016403707 title "877. Differential Expression of Indoleamine 2,3-dioxygenase (IDO) by Endothelial Cells and Its Overexpression by Gene Transfer: Implications for Cardiovascular Biology" @default.
• W2016403707 cites W1986231975 @default.
• W2016403707 cites W2052096938 @default.
• W2016403707 cites W2114749112 @default.
• W2016403707 doi "https://doi.org/10.1016/j.ymthe.2006.08.965" @default.
• W2016403707 hasPublicationYear "2006" @default.
• W2016403707 type Work @default.
• W2016403707 sameAs 2016403707 @default.
• W2016403707 citedByCount "0" @default.
• W2016403707 crossrefType "journal-article" @default.
• W2016403707 hasAuthorship W2016403707A5050282712 @default.
• W2016403707 hasAuthorship W2016403707A5056234160 @default.
• W2016403707 hasBestOaLocation W20164037071 @default.
• W2016403707 hasConcept C104317684 @default.
• W2016403707 hasConcept C123012128 @default.
• W2016403707 hasConcept C127561419 @default.
• W2016403707 hasConcept C202751555 @default.
• W2016403707 hasConcept C203014093 @default.
• W2016403707 hasConcept C2776706248 @default.
• W2016403707 hasConcept C2777411675 @default.
• W2016403707 hasConcept C2777702733 @default.
• W2016403707 hasConcept C515207424 @default.
• W2016403707 hasConcept C54009773 @default.
• W2016403707 hasConcept C54355233 @default.
• W2016403707 hasConcept C81885089 @default.
• W2016403707 hasConcept C83478079 @default.
• W2016403707 hasConcept C86803240 @default.
• W2016403707 hasConcept C8891405 @default.
• W2016403707 hasConcept C95444343 @default.
• W2016403707 hasConceptScore W2016403707C104317684 @default.
• W2016403707 hasConceptScore W2016403707C123012128 @default.
• W2016403707 hasConceptScore W2016403707C127561419 @default.
• W2016403707 hasConceptScore W2016403707C202751555 @default.
• W2016403707 hasConceptScore W2016403707C203014093 @default.
• W2016403707 hasConceptScore W2016403707C2776706248 @default.
• W2016403707 hasConceptScore W2016403707C2777411675 @default.
• W2016403707 hasConceptScore W2016403707C2777702733 @default.
• W2016403707 hasConceptScore W2016403707C515207424 @default.
• W2016403707 hasConceptScore W2016403707C54009773 @default.
• W2016403707 hasConceptScore W2016403707C54355233 @default.
• W2016403707 hasConceptScore W2016403707C81885089 @default.
• W2016403707 hasConceptScore W2016403707C83478079 @default.
• W2016403707 hasConceptScore W2016403707C86803240 @default.
• W2016403707 hasConceptScore W2016403707C8891405 @default.
• W2016403707 hasConceptScore W2016403707C95444343 @default.
• W2016403707 hasLocation W20164037071 @default.
• W2016403707 hasOpenAccess W2016403707 @default.
• W2016403707 hasPrimaryLocation W20164037071 @default.
• W2016403707 hasRelatedWork W1447489530 @default.
• W2016403707 hasRelatedWork W1972137566 @default.
• W2016403707 hasRelatedWork W2061395079 @default.
• W2016403707 hasRelatedWork W2220882815 @default.
• W2016403707 hasRelatedWork W2356902401 @default.
• W2016403707 hasRelatedWork W2371073660 @default.
• W2016403707 hasRelatedWork W2900608957 @default.
• W2016403707 hasRelatedWork W3028948306 @default.
• W2016403707 hasRelatedWork W4307291668 @default.
• W2016403707 hasRelatedWork W2118379210 @default.
• W2016403707 hasVolume "13" @default.
• W2016403707 isParatext "false" @default.
• W2016403707 isRetracted "false" @default.
• W2016403707 magId "2016403707" @default.
• W2016403707 workType "article" @default.